Answers are grounded in this paper and cite their sources.
A long-term analysis compares DNA-LNP and mRNA-LNP vaccines in Syrian hamsters, indicating DNA-LNP sustains immunity longer.
Abstract mRNA-lipid nanoparticle (LNP) vaccines induce robust adaptive immune responses and have proven highly effective against SARS-CoV-2. However, their long-term effectiveness is limited by waning humoral responses, which decline substantially within the first six months post-boost vaccination. DNA-LNPs are being investigated as an alternative vaccine platform, offering prolonged antigen expression and robust immunity. Here, we compare DNA- and mRNA-LNP vaccines encoding CD40L-adjuvanted SARS-CoV-2 XBB.1.5 Spike (S XBB.1.5 -CD40L) in a long-term in vivo challenge model. Both nucleic acid vaccines induced strong neutralizing antibody responses and conferred equivalent protection in Syrian hamsters challenged three weeks post-boost. Notably, DNA-LNP vaccination maintained high binding and neutralizing antibody titers six months post-boost, whereas mRNA-LNPs exhibited a marked decline. Correspondingly, while S XBB.1.5 -CD40L DNA-LNP vaccination completely protected from weight loss, viral replication, and lung pathology at this late timepoint, S XBB.1.5 -CD40L mRNA-LNP vaccination conferred minimal protection. These findings demonstrate that DNA-LNPs can sustain durable immunity, highlighting their potential as a next-generation vaccine platform that could reduce the need for frequent boosters.
No takes yet. Share an insight, caveat, or question.
Tamming et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: